Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
Jacqueline S. Garcia(Dana-Farber Cancer Institute), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), David Hoffman, Pierre Péterlin(Hotel Dieu Hospital), Huipei Wang(AbbVie (United States)), Maria R. Baer(University of Maryland, Baltimore), Chun Yew Fong(Olivia Newton-John Cancer Wellness & Research Centre), Grace Ku(University of California San Diego), Daniel Nowak(Heidelberg University), Olatoyosi Odenike(University of Chicago), Brenda Chyla(AbbVie (United States)), Uwe Platzbecker(National Center for Tumor Diseases), Jalaja Potluri(AbbVie (United States)), Shaun A Fleming(The Alfred Hospital), Meagan A. Jacoby(MACOM (United States)), Uma Borate(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 32
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783